Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.
A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...
So if you look at -- so the question is two-part. One, when you look at Lyrica’s mechanism of action, can you just compare and contrast versus VX-548 and how direct VX-548 versus Lyrica?